<DOC>
	<DOC>NCT02554942</DOC>
	<brief_summary>This study will evaluate the safety of subcutaneous (SC) epoetin beta (NeoRecormon) in adults with solid tumors being treated with platinum-based chemotherapy capable of inducing anemia. The anticipated time on study treatment is 16 weeks, and the target sample size is approximately 208 individuals.</brief_summary>
	<brief_title>A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Adults at least 18 years of age Presence of solid tumor(s) Receiving platinumbased therapy capable of inducing anemia Red blood cell transfusion within 7 days prior to study drug Relevant acute or chronic bleeding requiring therapy within 3 months prior to study drug Women who are pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>